Prospective evaluation of copy number alterations validates chromosome 1q gain as an independent marker of poor prognosis in localized Ewing sarcoma
This prospective study validates chromosome 1q gain as an independent marker of poor prognosis in localized Ewing sarcoma. Furthermore, the extent of genomic alteration emerges as a promising predictor of both OS and EFS. Incorporating these biomarkers may improve individualized risk stratification and ultimately enhance patient outcomes.
Authors
- Maite Blanquer-Maceiras
- Enrique de Álava (ORCID: https://orcid.org/0000-0001-8400-046X)
- Uta Dirksen (ORCID: https://orcid.org/0000-0002-5435-7860)
- Carmen Salguero‐Aranda (ORCID: https://orcid.org/0000-0001-6010-8302)
- Andreas Ranft (ORCID: https://orcid.org/0000-0003-4424-7569)
- Laura Romero‐Pérez (ORCID: https://orcid.org/0000-0003-3196-4382)
- Rosa Noguera (ORCID: https://orcid.org/0000-0003-4546-7459)
- Daniel Delgado‐Bellido (ORCID: https://orcid.org/0000-0002-9588-4747)
- Juan Díaz‐Martín (ORCID: https://orcid.org/0000-0002-3985-6434)
Institutions
- Universitat de València (ES)
- Essen University Hospital (DE)
- Instituto de Biomedicina de Sevilla (ES)
- Hospital Universitario Virgen del Rocío (ES)
- INCLIVA Health Research Institute (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- West German Heart and Vascular Center Essen (DE)
Publication Details
- Journal
- Experimental and Molecular Pathology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.yexmp.2025.105008
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00